Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HeraMEDASX:HMD -6.76% Net Cash per Share is A$0.00 as of Jun. 2026. The stock has 2 warning signs investors should review. Among 294 Medical Devices & Instruments companies, HeraMED ranks worse than 340135.71% on this metric.
The historical rank and industry rank for HeraMED's Net Cash per Share or its related term are showing as below:
During the past 8 years, the highest Price-to-Net-Cash Ratio of HeraMED was 27.88. The lowest was 3.91. And the median was 10.76.
ASX:HMD's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.3 * Ranked among companies with meaningful Price-to-Net-Cash only.
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
HeraMED Net Cash per Share Related Terms
HeraMED Net Cash per Share Historical Data
* Premium members only.
The historical data trend for HeraMED's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:HMD vs ABT, SYK, MDT: Net Cash per Share Comparison
For the Medical Devices subindustry, HeraMED's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HeraMED Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HeraMED's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where HeraMED's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
HeraMED's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HeraMED (ASX:HMD) has a Net Cash per Share of A$0.00 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on HeraMED and its competitors. According to the industry distribution chart, HeraMED ranks #999999 out of 294 companies in the Medical Devices & Instruments industry.
Is HeraMED's Net Cash per Share too high?
HeraMED's current Net Cash per Share is A$0.00. Based on the distribution chart, HeraMED ranks #999999 out of 294 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does HeraMED's Net Cash per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HeraMED ranks #999999 out of 294 companies for Net Cash per Share. This places HeraMED in the lower half of its industry. The industry median Net Cash per Share is 9.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 9.30, based on 294 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on HeraMED and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HeraMED's current Net Cash per Share is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeraMED stock overvalued right now?
Based on GuruFocus' analysis, HeraMED (ASX:HMD) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.03 — trading 72.5% above its estimated fair value. The current Net Cash per Share is A$0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For HeraMED (ASX:HMD), the current Net Cash per Share is A$0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HeraMED Ltd is a medical data and technology company providing the digital transformation of maternity care by revolutionizing the prenatal and postpartum experience with its hybrid maternity care platform. It offers a proprietary platform that utilizes hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence. Its offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, and allow healthcare professionals to provide the care and enable early detection and prevention of potential risks.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:HMD has been successfully added to your 
